Lipella Pharmaceuticals Inc. (NASDAQ:LIPO – Get Free Report)’s stock price was up 4.1% during mid-day trading on Friday . The stock traded as high as $0.47 and last traded at $0.46. Approximately 33,638 shares were traded during trading, a decline of 26% from the average daily volume of 45,392 shares. The stock had previously closed at $0.44.
Analysts Set New Price Targets
Separately, Maxim Group started coverage on Lipella Pharmaceuticals in a research note on Tuesday, April 9th. They set a “buy” rating and a $2.00 price target for the company.
Read Our Latest Research Report on Lipella Pharmaceuticals
Lipella Pharmaceuticals Stock Performance
Lipella Pharmaceuticals Company Profile
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
Read More
- Five stocks we like better than Lipella Pharmaceuticals
- How to Calculate Stock Profit
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- How to invest in marijuana stocks in 7 steps
- Qualcomm Stock Continues to Rise in the Face of Negative News
- Canada Bond Market Holiday: How to Invest and Trade
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
